Dr. Ismail-Khan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
893 Delaware Street
Indianapolis, IN 46225Phone+1 813-340-2252
Summary
- Roohi Ismail-Khan, MD, is an experienced oncologist based in Tampa, FL. She specializes in breast cancer, Gyn cancer, cardio-oncology, and clinical research. She completed her education and fellowship at the University of South Florida and Moffitt Cancer Center. She had a long clinical career at Moffitt in Breast Cancer, Gyn Cancer, and Cardio-Oncology. She completed her MSc in Clinical Research at USF. She now works in Global Drug Development at Eli Lilly Oncology as an Associate VP in Medical Oncology. She has an extensive record of publication in oncology and her clinical trial work focuses largely on breast cancer. Dr. Ismail-Khan is widely recognized in her field, garnering honors such as the Patient's Choice Award, Most Compassionate Doctor, and the "Physician of the Year" Award from Moffitt Cancer Center. She was recently awarded the prestigious LRL Presidential Award for her work in championing Diversity and Inclusion in Clinical Trials.
Education & Training
- University of South FloridaM.S.M.S., Clinical and Translational Research, Cum Laude, 2006 - 2010
- University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2005 - 2007
- University of South Florida MorsaniResidency, Internal Medicine, 2001 - 2004
- St. George's University School of MedicineClass of 2000
- Wesleyan CollegeBSc, Biology/Psychology/English, Summa Vum Laude, 1991 - 1995
Certifications & Licensure
- FL State Medical License 2005 - 2025
Awards, Honors, & Recognition
- LRL President’s Award Eli Lilly and Company, 2022
- Patient's Choice Award 2014, 2015 Vitals, 2015-2016
- Most Compassionate Doctor Vitals, 2014-2015
- Join now to see all
Clinical Trials
- A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
- A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients Start of enrollment: 2013 Feb 06
- COGNUTRIN in Breast Cancer Survivors Start of enrollment: 2014 Jul 30
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsImlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10 - Imlunestrant is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wildtype and Mutant Breast Cancer.Shripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao, Weihua Shen
Cancer Research. 2024-12-09 - A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Peter A Kaufman
Clinical Cancer Research. 2024-12-02
Journal Articles
- Beta-catenin Expression Patterns in Matched Pre and Post Neoadjuvant Chemotherapy Resistant Breast CancerRosa M, Han HS, Ismail-Khan R, Allam-Nandyala P, Bui M, Annals of Clinical and Laboratory Science, 1/1/2015
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumorsSoliman HH, Jackson E, Neuger T, Dees C, Harvey D, Han H, Ismail-Khan R, Minton SE, Vahanian N, Link C, Sullivan D, Antonia S, Oncotarget, 1/21/2014
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estro...Yardley D, Ismail-Khan R, Trepel J, et al, Journal Of Clinical Oncology, 1/6/2013
- Join now to see all
Abstracts/Posters
- A Phase II, open label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)Bardia A, Kummel S, Garcia-Estevez L, Huang CS, Cortes Castan J, Ruiz Borrego M, Telli ML, Lluch Hernandez A, Lopez R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz S, Maye..., ASCO, Chicago, IL, 1/1/2015
- The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple negative breast cancer clinical development and cli...Marchion DC, Xiong Y, Ismail-Khan R, Abbasi F, Bou Zgheib N, Ramirez IJ, Bush SH, Hakam A, Judson PL, Lancaster JM, SGO 45th Annual Meeting, Tampa, FL, 1/21/2014
- AKT survival signaling and phospho-AKT expression are associated with triple negative breast cancer development and clinical outcomeMarchion DC, Ismail-Khan R, Abbasi F, Boac B, Xiong Y, McClung C, Khulpateea BR, Bush SH, Hakam A, Lancaster JM, SGO 45th Annual Meeting, Tampa, FL, 1/21/2014
- Join now to see all
Lectures
- Cardiac Complications from Chemotherapy and The New Cardio-Oncology Program1/12/2015
- Issues in Breast Cancer TherapyUniversity of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL - 1/1/2015
- Triple Negative breast cancer1/1/2015
- Join now to see all
Other
- Cardio-Oncology: An Important New Specialty to Improve Patient OutcomesIsmail-Khan R and Fradley M
University of South Florida and Moffitt Cancer Center - 1/1/2015 - Triple Negative Breast CancerIsmail-Khan R, International Hospital and Equipment (IHE), PanGlobal Media
1/1/2010 - Why Focus on Triple Negative Breast Cancer?Ismail-Khan R, Factors Publications
Press Mentions
- Research ReportSeptember 28th, 2020
- Perspectives: The Benefit of Cardio- Oncology Programs for Cancer PatientsSeptember 28th, 2020
- Moffitt Cancer Center Takes Whole-Patient Treatment to HeartSeptember 28th, 2020
- Join now to see all
Professional Memberships
- Member
Other Languages
- Urdu, Hindi, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: